Updated on 10 July 2013
AstraZeneca has collaborated with Univ of Cambridge, Cancer Research UK to advance cancer research
Singapore: AstraZeneca has entered into an agreement with the University of Cambridge and Cancer Research UK for a two-year collaboration on three pre-clinical and clinical oncology projects. This agreement with world-leading medical research institutions based in UK, aims to advance cancer research through the study of tumor mutations and new investigational therapies in prostate, pancreatic and potentially other cancers.
The collaboration follows AstraZeneca's recent announcement that by 2016 its new UK-based global research and development center and corporate headquarters will be located at the Cambridge Biomedical Campus. This alliance will bring together scientists from AstraZeneca's small molecule and MedImmune's biologics units and researchers across the region from the University, affiliated Institutes and the NHS, all of which are members of the Cambridge Cancer Centre.
The three projects involve: working with the Cancer Research UK Cambridge Institute and the University of Cambridge Department of Oncology to evaluate a new technology that will allow clinicians to monitor the activity of a tumor - including its progression, response to therapy and the onset of drug resistance - through blood tests and without the need for biopsies. Based on the Cambridge Institute's pioneering techniques and AstraZeneca's treatment expertise, the aim of the collaboration is to use the tumor DNA present in a patient's blood to better understand the genetic makeup of their cancer and therefore the right therapy to tackle it.
Working with the Cancer Research UK Cambridge Institute, the University of Cambridge Department of Oncology at Addenbrooke's Hospital, and Cambridge University Hospitals to test the potential effectiveness of AstraZeneca's investigational therapies olaparib and AZD2014 in high-risk prostate cancer patients who currently have a poor disease prognosis. The compounds will be tested in both pre-clinical models and early-phase clinical trials.
Working with the Babraham Institute, the Cancer Research UK Cambridge Institute, and the University of Cambridge Department of Oncology at Addenbrooke's Hospital, to evaluate new therapeutic approaches for patients with pancreatic cancer, a disease with an extremely poor prognosis and few treatments available. The collaboration will focus on identifying the best drug combinations for AstraZeneca's investigational compound selumetinib in pre-clinical models.